Milka Maravic1, Natalia Hincapie2, Simon Pilet2, René-Marc Flipo3, Frédéric Lioté4. 1. Medical Department, AstraZeneca, 31, place des Corolles, 92400 Courbevoie, France. Electronic address: milka.maravic@astrazeneca.com. 2. Real-World Evidence Solutions, IMS Health, 92100 Boulogne-Billancourt, France. 3. Department of Rheumatology, University Hospital of Lille, University of Lille 2, 59000 Lille, France. 4. University Paris Diderot, Sorbonne Paris Cité, 75205 Paris, France; Department of Rheumatology, Hospital Lariboisière, AP-HP, Centre Viggo Petersen, 75010 Paris, France; Inserm, UMR 1132, Hospital Lariboisière, 75010 Paris, France.
Abstract
OBJECTIVE: To describe the characteristics and management of patients with gout in France during the year 2014. METHODS: Data were obtained from a computerized observational longitudinal patient database of a representative sample of 1200 general practitioners. Patients on urate-lowering treatment and/or colchicine were described by demographics and comorbidities, quality of management indicators (serum uric acid and renal function testing) and treatment (type of urate-lowering treatment, change and dose regimen). RESULTS: We identified 14,400 patients (84.4% men, mean age: 67.5 years) with gout in the database. The most frequent comorbidities were hypertension (70%), dyslipidemia (51%), diabetes (24%) and obesity (23%). The proportion with uric acid and renal function testing data was 32% and 29%, respectively. In gout patients, only 39% had a serum uric acid<6mg/dL. Among treated gout patients, 76% were receiving allopurinol at a mean dose lower than 200mg/d, most without any further change of dose regimen over one year. CONCLUSION: These data outlined the persistence of clinical inertia in 2014 for patients with gout.
OBJECTIVE: To describe the characteristics and management of patients with gout in France during the year 2014. METHODS: Data were obtained from a computerized observational longitudinal patient database of a representative sample of 1200 general practitioners. Patients on urate-lowering treatment and/or colchicine were described by demographics and comorbidities, quality of management indicators (serum uric acid and renal function testing) and treatment (type of urate-lowering treatment, change and dose regimen). RESULTS: We identified 14,400 patients (84.4% men, mean age: 67.5 years) with gout in the database. The most frequent comorbidities were hypertension (70%), dyslipidemia (51%), diabetes (24%) and obesity (23%). The proportion with uric acid and renal function testing data was 32% and 29%, respectively. In goutpatients, only 39% had a serum uric acid<6mg/dL. Among treated goutpatients, 76% were receiving allopurinol at a mean dose lower than 200mg/d, most without any further change of dose regimen over one year. CONCLUSION: These data outlined the persistence of clinical inertia in 2014 for patients with gout.
Authors: Fernando Perez Ruiz; Carlos A Sanchez-Piedra; Jesus T Sanchez-Costa; Mariano Andrés; Cesar Diaz-Torne; Mercedes Jimenez-Palop; Eugenio De Miguel; Carmen Moragues; Francisca Sivera Journal: Rheumatol Ther Date: 2017-12-04
Authors: Samantha S R Crossfield; Lana Yin Hui Lai; Sarah R Kingsbury; Paul Baxter; Owen Johnson; Philip G Conaghan; Mar Pujades-Rodriguez Journal: PLoS One Date: 2019-10-24 Impact factor: 3.240
Authors: Xiaomei Xue; Xuan Yuan; Lin Han; Xinde Li; Tony R Merriman; Lingling Cui; Zhen Liu; Wenyan Sun; Can Wang; Fei Yan; Yuwei He; Aichang Ji; Jie Lu; Changgui Li Journal: Front Med (Lausanne) Date: 2022-01-17